((自动化翻译由路透提供，请见免责声明 ))
10月18日 - ** 制药商吉利德 股价盘前下跌1%至86.48美元
** 该公司表示，在与美国食品和药物管理局（FDA）协商后，将自愿撤回 (link) 用于治疗先前接受过治疗的一种膀胱癌患者的药物 Trodelvy。
** Trodelvy 于 2021 年被 FDA 加速批准用于转移性尿路上皮癌，能否继续获批取决于确证试验的结果。
** 在试验中，该药物未能改善晚期膀胱癌患者的生存率
** 该决定不会影响美国境内外其他癌症患者使用 Trodelvy 的审批 - GILD
** 截至上一交易日收盘，股价累计上涨 7.8
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.